Semaglutide 10mg

RetaLABS Semaglutide 10mg is a lyophilised research vial of the benchmark GLP-1 receptor agonist — the most extensively characterised compound in the GLP-1 class with the longest peer-reviewed publication record. Developed by Novo Nordisk, Semaglutide is a 31-amino-acid GLP-1 analogue with C18 fatty-diacid acylation that produces a half-life of approximately 7 days, enabling once-weekly research protocols. The 10mg vial covers the full STEP 1 dose escalation from 0.25mg/week through to the 2.4mg/week maintenance dose — at peak dose, a single 10mg vial supplies approximately 4 weeks of research; at the 0.25mg starting dose it supplies 40 weeks.

Supplied as a white lyophilised powder. Shipped via Express Post Australia-wide in discrete, unmarked packaging — typically dispatched within 1–2 business days of confirmed crypto payment (BTC, LTC, or XMR).

Why Semaglutide Is the GLP-1 Class Benchmark

Semaglutide is the most extensively studied compound in the GLP-1 receptor agonist class — the reference point against which every subsequent compound is contextualised:

• Single-receptor mechanism. Semaglutide binds the GLP-1 receptor (GLP-1R) only. It does not engage the GIP receptor (Tirzepatide's second target) or the Glucagon receptor (Retatrutide's third target). The single-receptor profile makes Semaglutide the cleanest research reference for isolating pure GLP-1R signalling effects.
• Extended half-life via acylation. The C18 fatty-diacid chain at Lys²⁶ (with a γGlu-γGlu spacer) and the Aib² substitution that blocks DPP-4 cleavage together produce a 7-day half-life — the longest of the three primary GLP-1 class research peptides. Continuous albumin-bound circulation supports protocols requiring sustained receptor engagement without acute concentration spikes.
• Largest published evidence base. SUSTAIN (T2D outcomes), STEP (obesity), SELECT (cardiovascular outcomes in non-diabetic obesity), and ongoing programmes in NASH/MASH, Alzheimer's, addiction neuroscience, and heart failure. The breadth of published research provides the deepest reference dataset of any GLP-1 compound.

For the GLP-1 entity overview including the broader receptor-class context, see GLP-1 Explained.

STEP and SELECT Trial Data — What Researchers Are Working From

The pivotal STEP 1 trial (Wilding et al., NEJM 2021, NCT03548935) enrolled 1,961 adults with obesity (no T2D) over 68 weeks at the 2.4mg/week dose. Top-line outcomes:

Endpoint	Semaglutide 2.4mg	Placebo
Mean weight loss (68 weeks)	14.9%	2.4%
≥5% weight loss responders	~86%	~32%
≥10% weight loss responders	~69%	~12%
Waist circumference reduction	~13.5 cm	~4.1 cm

STEP 4 maintenance data is particularly relevant for researchers modelling discontinuation effects: participants who stopped Semaglutide regained approximately two-thirds of lost weight within 1 year, while those continuing maintained their loss — supporting the hypothesis that chronic GLP-1R engagement is required for sustained metabolic effects.

The SELECT trial (Lincoff et al., NEJM 2023, NCT03574597) extended Semaglutide research to cardiovascular outcomes in 17,604 adults with obesity and prior cardiovascular disease (no T2D) over a mean ~34-month follow-up. Result: 20% reduction in MACE (cardiovascular death, non-fatal MI, non-fatal stroke) versus placebo — the first MACE-reduction evidence for any GLP-1 compound in a non-diabetic population.

SUSTAIN-6 (cardiovascular outcomes in T2D, Marso et al., NEJM 2016) reported a 26% reduction in MACE versus placebo over 104 weeks, the original cardiovascular signal that established the GLP-1 class's broader metabolic-protection profile beyond glycaemic control.

Cross-Compound Comparison

Semaglutide is the single-receptor reference compound — the baseline against which Tirzepatide and Retatrutide's multi-receptor designs are evaluated. The following table is cross-trial (different populations, durations, dose designs — not head-to-head) and so direct ranking requires caution:

Metric	Semaglutide	Tirzepatide	Retatrutide
Receptor targets	GLP-1R	GLP-1R + GIPR	GLP-1R + GIPR + GcgR
Compound class	Single	Dual (twincretin)	Triple agonist
Developer	Novo Nordisk	Eli Lilly	Eli Lilly
Pivotal trial	STEP 1, 68 weeks	SURMOUNT-1, 72 weeks	Phase 2, 48 weeks
Trial enrolment	1,961	2,539	338
Highest dose	2.4mg/week	15mg/week	12mg/week
Mean weight loss (highest dose)	14.9%	20.9%	24.2%
Half-life	~7 days	~5 days	~6 days
Cardiovascular outcomes data	SUSTAIN-6 + SELECT (complete)	SURMOUNT-MMO ongoing	SYNERGY-OUTCOMES ongoing

For full side-by-side comparisons see Retatrutide vs Semaglutide and the GLP-1 Peptides Comparison Guide.

Reconstitution at a Glance

The most common research-protocol approach for a 10mg Semaglutide vial: add 1.0mL bacteriostatic water to produce a 10mg/mL working concentration. At this concentration, individual dose volumes on a standard U100 insulin syringe are:

Dose (STEP 1)	Volume at 10mg/mL	U100 syringe units	Doses per vial
0.25 mg (start)	0.025 mL	2.5 units	40
0.5 mg	0.05 mL	5 units	20
1.0 mg	0.10 mL	10 units	10
1.7 mg	0.17 mL	17 units	~5
2.4 mg (peak)	0.24 mL	24 units	~4

The 0.25mg and 0.5mg early-escalation doses produce sub-30-unit volumes that benefit from a 0.3mL low-dead-space U100 insulin syringe (or 0.5mL syringe) for precise volume control. Reconstitution technique: inject the bacteriostatic water slowly down the inner wall of the vial, swirl gently (do not shake), and store the reconstituted solution refrigerated at 2–8°C. The bacteriostatic water diluent contains 0.9% benzyl alcohol as a preservative, supporting multiple withdrawals from the same vial across an approximately 4-week stability window. For full protocol detail see the Peptide Reconstitution & Storage Guide and the reconstitution calculator.

Sourcing, Quality & Documentation

RetaLABS Semaglutide is supplied as research-grade, manufacturer-verified lyophilised peptide. Each batch is purity-tested by HPLC. Where a batch is published, its Certificate of Analysis appears on this page; full batch documentation is available on request — email support@retalabs.is with your order number.

All Semaglutide vials are supplied for laboratory research use only. Semaglutide has approved therapeutic registrations in multiple jurisdictions under different product brand names; the research-grade material supplied by RetaLABS is sold through a separate channel and is not the same product as approved therapeutic versions. By placing an order you confirm the compound is acquired for research purposes and not for human consumption.

Primary Research References

The core peer-reviewed publications underlying current Semaglutide research:

• Wilding JPH et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine, 2021; 384:989-1002. doi:10.1056/NEJMoa2032183. The pivotal STEP 1 trial — 14.9% mean weight loss at 2.4mg/week over 68 weeks. NCT03548935.
• Marso SP et al. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes." New England Journal of Medicine, 2016; 375:1834-1844. doi:10.1056/NEJMoa1607141. SUSTAIN-6 cardiovascular outcomes in T2D — 26% MACE reduction.
• Lincoff AM et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." New England Journal of Medicine, 2023; 389:2221-2232. doi:10.1056/NEJMoa2307563. SELECT trial — 20% MACE reduction in non-T2D obesity (n=17,604).
• Rubino D et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial." JAMA, 2021; 325:1414-1425. STEP 4 maintenance trial — discontinuation pattern reference. NCT03548987.
• Lau J et al. "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide." Journal of Medicinal Chemistry, 2015; 58:7370-7380. Original synthesis and pharmacokinetic characterisation — describes the Aib² + C18 diacid acylation design that extends half-life.
• ClinicalTrials.gov registrations: STEP 1 NCT03548935, STEP 4 NCT03548987, SUSTAIN-6 NCT01720446, SELECT NCT03574597.

The RetaLABS Research Team's editorial and sourcing methodology is documented at the RetaLABS Research Team profile.

Related Research Reading

• Semaglutide Research Guide — full mechanism, STEP + SUSTAIN + SELECT data, reconstitution
• Dosing Protocol Reference — STEP 1 escalation schedule + reconstitution maths
• GLP-1 Peptides Comparison Guide — Semaglutide vs Tirzepatide vs Retatrutide
• Retatrutide vs Semaglutide — triple agonist vs GLP-1 single-receptor comparison
• GLP-1 Explained — the hormone, the receptor, and the research-peptide class